OUR TECHnology

Our platform is uniquely able to target multiple misfolded protein aggregates implicated in serious diseases

AN URGENT NEED

Learn about our approach to meet the dire need for new treatments for neurodegenerative diseases

LATEST NEWS

Proclara Biosciences Appoints Suzanne Bruhn, Ph.D., as Chief Executive Officer to Guide Development of Novel Approach for Neurodegenerative Diseases